Recurrent complex partial status epilepticus associated with tiagabine rechallenge.
Brouns
R
R
Department of Neurology, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium.
Van Paesschen
W
W
D000085:Acetates / Q000008:administration & dosage; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D002220:Carbamazepine / Q000008:administration & dosage; D003509:Cyclohexanecarboxylic Acids; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000077206:Gabapentin; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008590:Meningoencephalitis / Q000150:complications; D009557:Nipecotic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D013226:Status Epilepticus / Q000139:chemically induced* / Q000503:physiopathology; D000078308:Tiagabine; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D009557:Nipecotic Acids; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D008140:Lorazepam; C028245:lorazepam acetate; D000078308:Tiagabine